Lv11
60 积分 2026-04-17 加入
Challenges facing CAR T-cell immunotherapy in multiple myeloma
18天前
已完结
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
18天前
已完结
Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma
25天前
已完结
Human herpesvirus 6 (HHV-6) encephalitis secondary to chimeric antigen receptor (CAR)-T cell therapy
1个月前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
1个月前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
1个月前
已完结
European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma
2个月前
已完结
Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies
2个月前
已完结
皖公网安备34019202002308
